SecBot SecBot
PRESS-RELEASE ·Filed May 6, 2026

TSHA

Taysha Gene Therapies, Inc.
MIXED
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The FDA alignment on a BLA submission pathway is the key catalyst, watch for the Part A data readout in Q2 2026 and completion of REVEAL dosing. The wider-than-expected loss and zero revenue are secondary to regulatory progress for a pre-revenue biotech. Monitor for any delays in the PPQ campaign or trial enrollment.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.98
T+0 close · May 6, 2026 · via day close
Latest settled
−16.05%
T+60 · $5.86
Vs SPY
−18.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $6.98entry
  2. T+1 · 6mo ago −4.44%α −4.11% · $6.67
  3. T+5 · 6mo ago −1.86%α −2.99% · $6.85
  4. T+20 · 6mo ago −20.49%α −23.27% · $5.55
  5. T+60 · 4mo ago −16.05%α −18.11% · $5.86
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Taysha reported Q1 2026 EPS of -$0.12 (GAAP), wider than the -$0.08 consensus, with zero revenue vs $2.3M a year ago. The stock will move on the FDA's reaffirmed alignment for a BLA submission for TSHA-102 based on the REVEAL pivotal trial's 6-month interim analysis, with dosing completion expected in Q2 2026.

Key Financial Metrics

EPS
−$0.12
est −$0.08 · -50.0%
Revenue
$0.00
est $758.0K · -100.0% · -100.0% YoY
Rating
miss

Key Facts

  • Q1 2026 GAAP net loss per share -$0.12 vs -$0.08 consensus (miss of 50%)
  • Revenue was $0, down from $2.3M in Q1 2025
  • Net loss widened to $42.4M from $21.5M YoY, driven by $33.8M R&D spend (up 117%)
  • Cash and equivalents $276.6M, expected to fund operations into 2028
  • FDA reaffirmed alignment on BLA pathway for TSHA-102, including potential submission based on REVEAL 6-month interim analysis
  • Dosing completion in REVEAL pivotal and ASPIRE trials expected in Q2 2026
  • BLA-enabling PPQ campaign initiated in April 2026, completion expected Q4 2026
  • No treatment-related SAEs or DLTs in REVEAL trials as of May 2026 data cutoff

Financial Impact

Net loss of $42.4M in Q1 2026, cash burn rate ~$43M/quarter, with $276.6M cash runway into 2028

revenuenet losscash positionR&D expenses

Risk Factors

  • Clinical trial failure or regulatory setback for TSHA-102
  • Cash burn rate may require future dilutive financing if timelines slip
  • Competition from other Rett syndrome therapies in development

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3288743

Track record

14 reports on TSHA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.50% at T+60 after the Jun 25, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
  2. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
  3. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
  4. Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
  5. Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
  6. Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
  7. Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
  8. May 6, 202627w ago 8-K Neutral 5/10 No price data
  9. May 6, 202627w ago Press Release Mixed 7/10 Viewing Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
  10. Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026